Suppr超能文献

肠道去污抑制 TLR4 依赖性纤维连接蛋白介导的肝纤维化小鼠星状细胞和内皮细胞之间的串扰。

Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.

机构信息

Gastroenterology Research Unit, Mayo Clinic and Foundation, Rochester, MN 55905, USA.

出版信息

J Hepatol. 2012 Apr;56(4):893-9. doi: 10.1016/j.jhep.2011.11.013. Epub 2011 Dec 13.

Abstract

BACKGROUND & AIMS: Liver fibrosis is associated with angiogenesis and leads to portal hypertension. Certain antibiotics reduce complications of liver failure in humans, however, the effects of antibiotics on the pathologic alterations of the disease are not fully understood. The aim of this study was to test whether the non-absorbable antibiotic rifaximin could attenuate fibrosis progression and portal hypertension in vivo, and explore potential mechanisms in vitro.

METHODS

The effect of rifaximin on portal pressure, fibrosis, and angiogenesis was examined in wild type and Toll-like receptor 4 (TLR4) mutant mice after bile duct ligation (BDL). In vitro studies were carried out to evaluate the effect of the bacterial product and TLR agonist lipopolysaccharide (LPS) on paracrine interactions between hepatic stellate cells (HSC) and liver endothelial cells (LEC) that lead to fibrosis and portal hypertension.

RESULTS

Portal pressure, fibrosis, and angiogenesis were significantly lower in BDL mice receiving rifaximin compared to BDL mice receiving vehicle. Studies in TLR4 mutant mice confirmed that the effect of rifaximin was dependent on LPS/TLR4 pathway. Fibronectin (FN) was increased in the BDL liver and was reduced by rifaximin administration and thus, was explored further in vitro as a potential mediator of paracrine interactions of HSC and LEC. In vitro, LPS promoted FN production from HSC. Furthermore, HSC-derived FN promoted LEC migration and angiogenesis.

CONCLUSIONS

These studies expand our understanding of the relationship of intestinal microbiota with fibrosis development by identifying FN as a TLR4 dependent mediator of the matrix and vascular changes that characterize cirrhosis.

摘要

背景与目的

肝纤维化与血管生成有关,并导致门脉高压。某些抗生素可减少人类肝功能衰竭的并发症,但抗生素对疾病病理改变的影响尚未完全了解。本研究旨在检测不吸收抗生素利福昔明是否能减轻体内肝纤维化进展和门脉高压,并在体外探索潜在机制。

方法

在胆管结扎(BDL)后,检测利福昔明对野生型和 Toll 样受体 4(TLR4)突变小鼠的门脉压、纤维化和血管生成的影响。体外研究评估细菌产物和 TLR 激动剂脂多糖(LPS)对导致纤维化和门脉高压的肝星状细胞(HSC)和肝内皮细胞(LEC)之间旁分泌相互作用的影响。

结果

与接受载体的 BDL 小鼠相比,接受利福昔明的 BDL 小鼠的门脉压、纤维化和血管生成明显降低。在 TLR4 突变小鼠中的研究证实,利福昔明的作用依赖于 LPS/TLR4 途径。纤维连接蛋白(FN)在 BDL 肝脏中增加,利福昔明给药后减少,因此,在体外进一步研究作为 HSC 和 LEC 旁分泌相互作用的潜在介质。在体外,LPS 促进 HSC 产生 FN。此外,HSC 衍生的 FN 促进 LEC 迁移和血管生成。

结论

这些研究通过鉴定 FN 作为 TLR4 依赖性基质和血管变化的介质,扩展了我们对肠道微生物群与纤维化发展之间关系的理解,这些变化是肝硬化的特征。

相似文献

引用本文的文献

7
Sinusoidal communication in chronic liver disease.慢性肝病中的窦状隙通讯
Clin Mol Hepatol. 2025 Jan;31(1):32-55. doi: 10.3350/cmh.2024.0734. Epub 2024 Oct 2.
9
Liver cirrhosis and complications from the perspective of dysbiosis.从菌群失调角度看肝硬化及其并发症
Front Med (Lausanne). 2024 Jan 16;10:1320015. doi: 10.3389/fmed.2023.1320015. eCollection 2023.

本文引用的文献

5
Biologic properties and clinical uses of rifaximin.利福昔明的生物学特性和临床用途。
Expert Opin Pharmacother. 2011 Feb;12(2):293-302. doi: 10.1517/14656566.2011.546347.
7
Drug therapy: rifaximin.药物治疗:利福昔明。
Hepatology. 2010 Oct;52(4):1484-8. doi: 10.1002/hep.23866.
9
Toll-like receptor 4 and hepatic fibrogenesis. toll 样受体 4 与肝纤维化。
Semin Liver Dis. 2010 Aug;30(3):232-44. doi: 10.1055/s-0030-1255353. Epub 2010 Jul 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验